Transplant, Cancer Patients Among First to Get Evusheld at UC San Diego Health
UC San Diego Health is now administering Evusheld to eligible, immunocompromised patients to protect against the COVID-19 virus.
UC San Diego Health Sciences schools, institutes and centers are at the forefront of discovery and transformation.
UC San Diego Health is now administering Evusheld to eligible, immunocompromised patients to protect against the COVID-19 virus.
Years of toil in the laboratory have revealed how a marine bacterium makes a potent anti-cancer molecule. Researchers at UC San Diego’s Scripps Institution of Oceanography found that an enzyme called SalC assembles what the team calls the salinosporamide anti-cancer “warhead.”
UC San Diego study shows neuroendocrine cells in the lungs drive a developmental lung disease, and a similar brain-lung interaction may contribute to COVID-19 symptoms. The findings suggest neuropeptides may be a promising therapeutic target for conditions with excess lung fluid.
The All of Us Research Program, a nationwide effort to gather information from 1 million or more people living in the United States, then use that data to accelerate health research and medical breakthroughs, has published its first genomic dataset.
The U.S. Agency for International Development has funded a $38 million, five-year project led by UC San Diego researchers to better understand and promote health agency for individuals, communities and local organizations in low- and middle-income countries.
UC San Diego Health is the first hospital system in San Diego County to employ high-intensity, focused ultrasound (HIFU) for minimally invasive prostate cancer treatment.
Forbes, May 29
San Diego Union Tribune, May 28
Keep up with all the latest from UC San Diego. Subscribe to the newsletter today.
You have been successfully subscribed to the UC San Diego Today Newsletter.